| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Hannah Mamuszka last filed a Form 4 in June 2025, as Director at BNGO. Hannah Mamuszka's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 65,789 shares of BNGO. Net of sales, the BNGO filings show accumulation of 65,789 shares.
Hannah Mamuszka has 9 Form 4 filings on record from May 2020 to June 2025, all as Director at Bionano Genomics (BNGO), 2020–2025.
The 9 reported transactions were 8 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $50K and no sales.
The only open-market purchase was 65,789 shares of BNGO at an average $0.76 on June 13, 2023, about $50K. Twelve months later BNGO was down 89%.
Shares as reported in the last Form 4 for each company; the most recent is from June 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 13, 2023 | BNGO Bionano Genomics, Inc. | Director | Buy | 65,789 | $0.76 | $49,999.64 | New | -53.9% | -89.0% |